bladder cancer
Showing NaN - NaN of 59
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Bladder Cancer Trial in Worldwide (Atezolizumab)
Active, not recruiting
- Bladder Cancer
-
Birmingham, Alabama
- +76 more
Dec 6, 2022
Bladder Cancer Trial in Worldwide (Atezolizumab)
Active, not recruiting
- Bladder Cancer
-
Birmingham, Alabama
- +76 more
Dec 6, 2022
Intravesical Therapy and Surgery as Treatment Options for
Recruiting
- Bladder Cancer
- +2 more
-
Birmingham, Alabama
- +37 more
Nov 28, 2022
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))
Available
- Pancreatic Cancer
- +20 more
- Ulixertinib (BVD-523)
-
Birmingham, Alabama
- +25 more
Nov 4, 2022
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma Trial in France, United States (TRK-950, Irinotecan, Leucovorin)
Recruiting
- Solid Tumor
- +11 more
- TRK-950
- +14 more
-
Scottsdale, Arizona
- +13 more
Oct 2, 2022
Urothelial Carcinoma, Bladder Cancer Trial in United States (Placebo, Pembrolizumab)
Completed
- Urothelial Carcinoma
- Bladder Cancer
- Placebo
- Pembrolizumab
-
Phoenix, Arizona
- +27 more
Sep 16, 2022
Bladder Cancer Trial in Canada, United States (therapeutic conventional surgery, therapeutic standard lymphadenectomy,
Active, not recruiting
- Bladder Cancer
- therapeutic conventional surgery
- +2 more
-
Los Angeles, California
- +34 more
Jul 20, 2022
Bladder Cancer, Urothelial Carcinoma Trial in United States (OGX-427, Docetaxel)
Completed
- Bladder Cancer
- Urothelial Carcinoma
-
Birmingham, Alabama
- +34 more
Jul 7, 2022
A Diagnostic for the Early Detection of Bladder Cancer
Recruiting
- Bladder Cancer
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Apr 29, 2022
A Novel Multiplex ELISA Assay for Surveilling History of Bladder
Active, not recruiting
- Bladder Cancer
-
Los Angeles, California
- +3 more
Apr 5, 2022
Ovarian Cancer, Hepatocellular Carcinoma, NSCLC Trial in Canada, United States (DPX-Survivac, Cyclophosphamide, Pembrolizumab)
Active, not recruiting
- Ovarian Cancer
- +4 more
- DPX-Survivac
- +2 more
-
Tucson, Arizona
- +22 more
Mar 28, 2022
A Novel Multiplex ELISA Assay for Evaluating Microscopic
Recruiting
- Bladder Cancer
-
Los Angeles, California
- +1 more
Mar 7, 2022
A Novel Multiplex ELISA Assay for Evaluating Gross Hematuria for
Recruiting
- Bladder Cancer
-
Los Angeles, California
- +3 more
Mar 7, 2022
Predicting BCG Response
Recruiting
- Bladder Cancer
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Mar 7, 2022
Urothelial Carcinoma, Bladder Cancer, Urethral Cancer Trial in United States (Biospecimen Collection)
Active, not recruiting
- Urothelial Carcinoma
- +3 more
- Biospecimen Collection
-
Los Angeles, California
- +7 more
Feb 14, 2022
Prostate Cancer, Melanoma, Renal Cell Carcinoma Trial in United States (MGA271)
Completed
- Prostate Cancer
- +6 more
- MGA271
-
Los Angeles, California
- +11 more
Feb 4, 2022
Mesothelioma, Bladder Cancer, Melanoma Trial in Australia, Canada, United States (MGD009)
Terminated
- Mesothelioma
- +12 more
- MGD009
-
Los Angeles, California
- +19 more
Feb 4, 2022
Bladder Cancer, Urinary Bladder Tumor, Urologic Tumors Trial in Los Angeles, Boston (Fiducial marker placement, Multiparametric
Recruiting
- Bladder Cancer
- +4 more
- Fiducial marker placement
- Multiparametric MRI (mpMRI)
-
Los Angeles, California
- +1 more
Jan 7, 2022